The development and use of immunotherapy in Africa
The development and use of immunotherapy in Africa
复制标题
DOI：
10.1016/s0041-0101(98)00140-8
复制
发表时间：
1998-11-01
期刊：
影响因子：
2.8
通讯作者：
Chippaux, JP
中科院分区：
文献类型：
--
作者：
Chippaux, JP
由于抗蛇毒血清纯化技术的改进以及毒理学和药理学研究的成果，免疫治疗是近年来发展起来的。使用高度纯化的IgG片段可获得更好的耐受性和更高的疗效。象在许多热带国家一样，蛇中毒在非洲是一个重要的公共卫生问题。每年蛇咬伤的发生率达到100万，每年的死亡率约为2万人。不到25%的抗蛇毒血清需求得到有效覆盖，而且可能在大多数中毒中，使用剂量不足。通过更好地了解蛇咬伤流行病学、标准化治疗和培训医务人员以及为抗蛇毒血清供应制定新的财务程序，可以改善蛇咬伤的治疗。(C) 1998 Elsevier Science Ltd.出版版权所有。
The immunotherapy was recently developed due to the improvement of purification techniques of antivenoms and results of the research in toxicology and pharmacology. The utilisation of highly purified IgG fragments leads to a better tolerance and a higher efficacy. Snake envenomations constitute in Africa, as in many tropical countries, an important public health problem. The annual incidence of snakebites reaches I million and the annual mortality is about 20,000 deaths. Less than 25% of the antivenom needs are effectively covered and, probably in most of envenomations, used at insufficient doses. The treatment of snakebites would be improved by better knowledge on snakebite epidemiology, standardisation of treatment and training medical staff, and development of new financial procedures for antivenom supply. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.